Polycythemia vera epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
Line 14: Line 14:


===Age===
===Age===
The median age of polycythemia vera is 61 years.<ref name="pmid26324368">{{cite journal| author=Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK et al.| title=Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F. | journal=J Clin Oncol | year= 2015 | volume= 33 | issue= 33 | pages= 3953-60 | pmid=26324368 | doi=10.1200/JCO.2015.61.6474 | pmc=4979103 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26324368  }} </ref><ref name="pmid25353086">{{cite journal| author=Verstovsek S, Komrokji RS| title=Novel and emerging therapies for the treatment of polycythemia vera. | journal=Expert Rev Hematol | year= 2015 | volume= 8 | issue= 1 | pages= 101-13 | pmid=25353086 | doi=10.1586/17474086.2015.972359 | pmc=4934659 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25353086  }} </ref> Polycythemia vera occurs in all age groups (including children). The incidence increases with age. Polycythemia vera commonly affects people older than 60.<ref name="seercancergov">National Cancer Institute. Polycythemia vera 2015.http://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd538d/</ref><ref>{{cite journal | author = Passamonti F, Malabarba L, Orlandi E, Baratè C, Canevari A, Brusamolino E, Bonfichi M, Arcaini L, Caberlon S, Pascutto C, Lazzarino M | title = Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. | journal = Haematologica | volume = 88 | issue = 1 | pages = 13-8 | year = 2003 | id = PMID 12551821}}</ref><ref name="pvsg">Berlin, NI. (1975). "Diagnosis and classification of polycythemias". ''Semin Hematol'' '''12''': 339.</ref> Younger patients are more likely to develop unusual complications such as mesenteric venous thrombosis. The rate of transformation to acute leukemia is similar as that of older adults.<ref name="pmid26324368">{{cite journal| author=Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK et al.| title=Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F. | journal=J Clin Oncol | year= 2015 | volume= 33 | issue= 33 | pages= 3953-60 | pmid=26324368 | doi=10.1200/JCO.2015.61.6474 | pmc=4979103 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26324368  }} </ref>
The median age of polycythemia vera is 61 years.<ref name="pmid26324368">{{cite journal| author=Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK et al.| title=Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F. | journal=J Clin Oncol | year= 2015 | volume= 33 | issue= 33 | pages= 3953-60 | pmid=26324368 | doi=10.1200/JCO.2015.61.6474 | pmc=4979103 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26324368  }} </ref><ref name="pmid25353086">{{cite journal| author=Verstovsek S, Komrokji RS| title=Novel and emerging therapies for the treatment of polycythemia vera. | journal=Expert Rev Hematol | year= 2015 | volume= 8 | issue= 1 | pages= 101-13 | pmid=25353086 | doi=10.1586/17474086.2015.972359 | pmc=4934659 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25353086  }} </ref> Polycythemia vera occurs in all age groups (including children). The incidence increases with age. Polycythemia vera commonly affects people older than 60 since mutations are more likely to develop with aging.<ref name="seercancergov">National Cancer Institute. Polycythemia vera 2015.http://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd538d/</ref><ref>{{cite journal | author = Passamonti F, Malabarba L, Orlandi E, Baratè C, Canevari A, Brusamolino E, Bonfichi M, Arcaini L, Caberlon S, Pascutto C, Lazzarino M | title = Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. | journal = Haematologica | volume = 88 | issue = 1 | pages = 13-8 | year = 2003 | id = PMID 12551821}}</ref><ref name="pvsg">Berlin, NI. (1975). "Diagnosis and classification of polycythemias". ''Semin Hematol'' '''12''': 339.</ref> Younger patients are more likely to develop unusual complications such as mesenteric venous thrombosis. The rate of transformation to acute leukemia is similar as that of older adults.<ref name="pmid26324368">{{cite journal| author=Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK et al.| title=Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F. | journal=J Clin Oncol | year= 2015 | volume= 33 | issue= 33 | pages= 3953-60 | pmid=26324368 | doi=10.1200/JCO.2015.61.6474 | pmc=4979103 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26324368  }} </ref>


===Gender===
===Gender===

Revision as of 00:59, 19 February 2018

Polycythemia vera Microchapters

Home

Patient Information

Overview

Historical perspective

Classification

Pathophysiology

Causes

Differentiating Polycythemia vera from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural history, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Polycythemia vera epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Polycythemia vera epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Polycythemia vera epidemiology and demographics

CDC on Polycythemia vera epidemiology and demographics

Polycythemia vera epidemiology and demographics in the news

Blogs on Polycythemia vera epidemiology and demographics

Directions to Hospitals Treating Polycythemia vera

Risk calculators and risk factors for Polycythemia vera epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2] Shyam Patel [3]

Overview

The incidence of polycythemia vera is approximately 0.7 to 2.6 per 100,000 individuals in the US.[1]

Epidemiology and Demographics

Incidence

The incidence of polycythemia vera is approximately 0.7 to 2.6 per 100,000 individuals in the US.[1]

Prevalence

The prevalence of polycythemia vera is 48 to 57 cases per 100,000 individuals in the United States. This represents the age-adjusted prevalence as of 2010. The prevalence of polycythemia vera is 5 to 30 cases per 100,000 individuals in Europe.[2] Approximately 148,000 persons are living with polycythemia vera currently.[3] It is likely that this is an underestimate of the true prevalence, as many patients are asymptomatic.[3]

Age

The median age of polycythemia vera is 61 years.[3][2] Polycythemia vera occurs in all age groups (including children). The incidence increases with age. Polycythemia vera commonly affects people older than 60 since mutations are more likely to develop with aging.[1][4][5] Younger patients are more likely to develop unusual complications such as mesenteric venous thrombosis. The rate of transformation to acute leukemia is similar as that of older adults.[3]

Gender

Males are more commonly affected with polycythemia vera than females, with a male to female ratio of 6.5:3.5.[1][2][2] However, in patients under age 40, there is a female predominance of 7.5:2.5.

Life expectancy

The life expectancy after diagnosis is 13.5 years.[2]

References

  1. 1.0 1.1 1.2 1.3 National Cancer Institute. Polycythemia vera 2015.http://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd538d/
  2. 2.0 2.1 2.2 2.3 2.4 Verstovsek S, Komrokji RS (2015). "Novel and emerging therapies for the treatment of polycythemia vera". Expert Rev Hematol. 8 (1): 101–13. doi:10.1586/17474086.2015.972359. PMC 4934659. PMID 25353086.
  3. 3.0 3.1 3.2 3.3 Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK; et al. (2015). "Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F". J Clin Oncol. 33 (33): 3953–60. doi:10.1200/JCO.2015.61.6474. PMC 4979103. PMID 26324368.
  4. Passamonti F, Malabarba L, Orlandi E, Baratè C, Canevari A, Brusamolino E, Bonfichi M, Arcaini L, Caberlon S, Pascutto C, Lazzarino M (2003). "Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia". Haematologica. 88 (1): 13–8. PMID 12551821.
  5. Berlin, NI. (1975). "Diagnosis and classification of polycythemias". Semin Hematol 12: 339.

Template:Hematology


Template:WikiDoc Sources